180 Participants Needed

Cannabidiol for Alcohol Use Disorder

RM
JL
Overseen ByJaime Laurin, MS
Prior Safety DataThis treatment has passed at least one previous human trial

Trial Summary

What is the purpose of this trial?

This is a double-blind, placebo-controlled, parallel group study designed to assess the efficacy of full spectrum CBD and broad spectrum CBD, compared to a placebo control (PC), to reduce drinking in participants with alcohol use disorder. If eligible for the study, subjects will be randomized to receive one of the conditions for 12 weeks.

Will I have to stop taking my current medications?

You may need to stop taking certain medications if they interact with Epidiolex, are antiepileptic, or affect alcohol intake, like disulfiram, naltrexone, acamprosate, or topiramate.

What evidence supports the effectiveness of the drug Cannabidiol (CBD) for treating alcohol use disorder?

Research in mice shows that CBD can reduce alcohol consumption, motivation to drink, and relapse, suggesting it might help with alcohol use disorder. Additionally, a systematic review indicates that CBD has potential benefits in reducing alcohol-related harms and addiction behaviors in preclinical models, although more human studies are needed to confirm these effects.12345

Is cannabidiol (CBD) safe for humans?

Research suggests that cannabidiol (CBD) is generally well tolerated in humans, with no significant interactions with alcohol's effects and no abuse potential. However, more human studies are needed to confirm its safety profile.34567

How is the drug Cannabidiol (CBD) unique in treating alcohol use disorder?

Cannabidiol (CBD) is unique because it is a nonpsychoactive component of cannabis that has shown promise in reducing alcohol consumption and related harms in preclinical models, without the risk of abuse. Unlike traditional treatments, CBD may offer neuroprotective benefits and reduce alcohol-induced liver damage, but more human studies are needed to confirm these effects.34578

Research Team

KH

Kent Hutchison, PhD

Principal Investigator

University of Colorado, Denver

Eligibility Criteria

This trial is for adults over 21 with moderate to severe Alcohol Use Disorder who drink heavily and want to cut down or stop. They must be able to visit the study site, not use cannabis daily, have no serious psychiatric disorders or recent medical issues, and not take certain medications that affect alcohol intake.

Inclusion Criteria

I want to cut down or stop drinking alcohol.
Participants reporting current nicotine use in any form will be included
I am 21 years old or older.
See 3 more

Exclusion Criteria

I use CBD products for health reasons.
Endorsing item 2 on the C-SSRS measure of suicide risk
Lack of access to internet
See 13 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either full spectrum CBD, broad spectrum CBD, or placebo for 12 weeks to assess efficacy in reducing alcohol consumption and related symptoms

12 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

Treatment Details

Interventions

  • Cannabidiol
  • Placebo
Trial OverviewThe study tests full spectrum CBD and broad spectrum CBD against a placebo in reducing alcohol consumption over 12 weeks. Participants are randomly assigned one of these options without knowing which one they receive (double-blind).
Participant Groups
3Treatment groups
Active Control
Placebo Group
Group I: Full-Spectrum CannabidiolActive Control1 Intervention
210mg/day of full-spectrum cannabidiol, containing less than 0.3% THC.
Group II: Broad-Spectrum CannabidiolActive Control1 Intervention
210mg/day of full-spectrum cannabidiol, containing 0.0% THC.
Group III: PlaceboPlacebo Group1 Intervention
210mg/day of hemp seed oil with no cannabinoids present.

Cannabidiol is already approved in United States, European Union, Canada for the following indications:

🇺🇸
Approved in United States as Epidiolex for:
  • Seizures associated with Lennox-Gastaut syndrome
  • Seizures associated with Dravet syndrome
  • Seizures associated with tuberous sclerosis complex
🇪🇺
Approved in European Union as Epidiolex for:
  • Seizures associated with Lennox-Gastaut syndrome
  • Seizures associated with Dravet syndrome
  • Seizures associated with tuberous sclerosis complex
🇨🇦
Approved in Canada as Epidiolex for:
  • Seizures associated with Lennox-Gastaut syndrome
  • Seizures associated with Dravet syndrome

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Colorado, Denver

Lead Sponsor

Trials
1,842
Recruited
3,028,000+

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Collaborator

Trials
865
Recruited
1,091,000+

Findings from Research

The combination of low doses of naltrexone and cannabidiol (CBD) significantly reduced alcohol consumption and motivation to drink in mice more effectively than either drug alone, suggesting a synergistic effect.
This enhanced efficacy is linked to changes in gene expression related to opioid and serotonin receptors, particularly the 5-HT1A receptor, indicating that these receptors play a crucial role in the mechanism of action for the drug combination.
Effects of cannabidiol plus naltrexone on motivation and ethanol consumption.Viudez-Martínez, A., García-Gutiérrez, MS., Fraguas-Sánchez, AI., et al.[2021]
A review of 207 studies identified only 3 randomized clinical trials (RCTs) specifically focused on using cannabidiol (CBD) for cannabis use disorder, highlighting a significant gap in research for CBD's efficacy in treating substance use disorders.
Ongoing trials are enhancing outcome measures by incorporating peripheral biomarkers from the endocannabinoid system, which may help predict how well individuals respond to CBD treatment.
Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers.Morel, A., Lebard, P., Dereux, A., et al.[2021]
Cannabidiol (CBD) shows promise as a potential treatment for alcohol use disorder (AUD), demonstrating neuroprotective effects and reducing alcohol-related harms in rodent models, including decreased alcohol self-administration and withdrawal symptoms.
In human studies, CBD was well tolerated and did not affect the subjective experience of alcohol, suggesting it may be a safe option for further investigation in treating AUD, although more human clinical trials are needed to confirm its efficacy.
Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review.Turna, J., Syan, SK., Frey, BN., et al.[2020]

References

Effects of cannabidiol plus naltrexone on motivation and ethanol consumption. [2021]
Clinical Trials of Cannabidiol for Substance Use Disorders: Outcome Measures, Surrogate Endpoints, and Biomarkers. [2021]
Cannabidiol as a Novel Candidate Alcohol Use Disorder Pharmacotherapy: A Systematic Review. [2020]
Cannabidiol reduces ethanol consumption, motivation and relapse in mice. [2019]
Oral Cannabidiol does not alter Alcohol Seeking and Self-Administration in Baboons. [2023]
Cannabidiol as a candidate pharmacotherapy for sleep disturbance in alcohol use disorder. [2023]
Consuming oral cannabidiol prior to a standard alcohol dose has minimal effect on breath alcohol level and subjective effects of alcohol. [2023]
THC and CBD effects on alcohol use among alcohol and cannabis co-users. [2021]